Company / Capital Expenditures
Inhibikase Therapeutics, Inc. Capital Expenditures History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$14.2K
FY2024
5-year range
$0 / $243.3K
FY2022-FY2024
Trend
-94.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $0 to $14,238 over the past 2 years.
Based on SEC 10-K filings.
$14,238 in FY2024.
Improved from $0 to $14,238 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, capital expenditures decreased 94.1% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $14.2K | -94.1% |
| FY2023 | $243.3K | - |
| FY2022 | $0 | - |
| FY2021 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026